secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001641172-25-009949
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate
--------------------------------------------------------------------------------

- Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
- Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.
- PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.
- U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.
- Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/0001641172-25-009949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer